Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics, Inc. is a clinical-stage biotech developing conditionally activated cytokine therapies and T‑cell engagers for cancer and immune diseases using its PREDATOR platform. The company discloses substantial doubt about its ability to continue as a going concern and is exploring strategic alternatives, including a possible sale or merger.
In February 2026 it adopted a restructuring plan, reducing its workforce by 64% and expecting about $4.1 million of severance and related charges in the first quarter of 2026. Lead IL‑2 INDUKINE candidate WTX‑124 showed a 21% objective response rate as monotherapy in heavily pretreated metastatic melanoma and 30% in patients who were not primary resistant to immunotherapy, with an FDA‑accepted 18 mg recommended dose and initial monotherapy registration guidance in post‑ICI melanoma. IL‑12 INDUKINE WTX‑330 produced a confirmed partial response in metastatic gall bladder cancer with a 45% tumor reduction and favorable pharmacokinetics. Further advancement of all programs depends on additional funding and outcomes of the strategic review.